NeoGenomics (NEO) Tops Q3 EPS by 3c, Beats on Revenues; Lifts FY18 EPS/Revenue Outlook Above Consensus
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Qtrex Quantum executives plan to buy up to 2M shares over 12 months
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
NeoGenomics Reports 17% Revenue Growth to Record $69 Million
October 30, 2018 7:00 AM EDTFT. MYERS, Fla., Oct. 30, 2018 (GLOBE NEWSWIRE) -- NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic testing services, today reported its results for the third quarter of 2018.
Third Quarter 2018 Highlights:
  17% increase in consolidated revenueÂ
  14% increase in clinical genetic testing volume(1)
  21% increase in Pharma Services revenue; 75% increase in Pharma Services backlog
  Completed $135 million, net equity offering
  Announced acquisition of Genoptix in October for $125 million in cash and 1 million shares of NeoGenomics common... More
